Analysis: Ventria on ITC win barring rHSA products

Last month, October 2022, the US International Trade Commission ( ITC) affirmed an administrative law judge’s (ALJ’s) finding that products containing recombinant human serum albumins (rHSAs) made by a Chinese company infringe a patent belonging to Ventria Bioscience.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Ozempic goes generic as Novo’s key patent expires

20 March 2026 As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.

Americas

Masimo convinces judge that Apple took secrets—but it’s not enough

19 March 2026 Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

More features

Ozempic goes generic as Novo’s key patent expires

Masimo convinces judge that Apple took secrets—but it’s not enough

Sandoz strikes fresh biosimilar deal with South Korean biotech

US firm boosts patent bench with Desmarais hire

J&J unit targets former employee over alleged mass data theft

HSF Kramer hires patent litigator as partner in Germany

INTA: ‘New normal’ for in-house counsel as budgets fall

Mylan withdraws defence claims against Novo in Wegovy dispute

Analysis: Ventria on ITC win barring rHSA products

More on this story

Editor's picks

Editor's picks

More features